Huntingtons Disease - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 277 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Huntington's Disease - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Huntington's Disease - Pipeline Review, H2 2014', provides an overview of the Huntington's Disease's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Huntington's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Huntington's Disease and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Huntington's Disease
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Huntington's Disease and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Huntington's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Huntington's Disease pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Huntington's Disease
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Huntington's Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Huntington's Disease Overview 10
Therapeutics Development 11
Pipeline Products for Huntington's Disease - Overview 11
Pipeline Products for Huntington's Disease - Comparative Analysis 12
Huntington's Disease - Therapeutics under Development by Companies 13
Huntington's Disease - Therapeutics under Investigation by Universities/Institutes 18
Huntington's Disease - Pipeline Products Glance 21
Late Stage Products 21
Clinical Stage Products 22
Early Stage Products 23
Huntington's Disease - Products under Development by Companies 24
Huntington's Disease - Products under Investigation by Universities/Institutes 28
Huntington's Disease - Companies Involved in Therapeutics Development 30
NsGene A/S 30
Isis Pharmaceuticals, Inc. 31
Sangamo BioSciences, Inc. 32
Ipsen S.A. 33
Pfizer Inc. 34
Teva Pharmaceutical Industries Limited 35
Vertex Pharmaceuticals Incorporated 36
BrainStorm Cell Therapeutics Inc. 37
Addex Therapeutics Ltd 38
Evotec AG 39
Neuralstem, Inc. 40
Living Cell Technologies Limited 41
Cortex Pharmaceuticals, Inc. 42
Acadia Pharmaceuticals Inc. 43
Alnylam Pharmaceuticals, Inc. 44
Prana Biotechnology Limited 45
CrystalGenomics, Inc. 46
Oryzon Genomics S.A. 47
Auspex Pharmaceuticals, Inc. 48
reMYND 49
Trophos SA 50
NeuroNascent, Inc. 51
Azevan Pharmaceuticals, Inc. 52
Siena Biotech S.p.A. 53
KineMed, Inc. 54
Omeros Corporation 55
Provid Pharmaceuticals, Inc. 56
Galenea Corp. 57
Genethon 58
Vybion, Inc. 59
Treventis Corporation 60
Varinel, Inc. 61
Prosensa Therapeutics B.V. 62
VivaCell Biotechnology Espana S.L. 63
Medesis Pharma S.A. 64
Genervon Biopharmaceuticals, LLC 65
BioCrea GmbH 66
Zenobia Therapeutics, Inc. 67
AlzProtect SAS 68
SOM Biotech SL 69
Valens Therapeutics, Inc. 70
EncephRx, Inc. 71
Chronos Therapeutics Limited 72
UniQure NV 73
Angita B.V. 74
Saniona AB 75
Huntington's Disease - Therapeutics Assessment 76
Assessment by Monotherapy Products 76
Assessment by Target 77
Assessment by Mechanism of Action 81
Assessment by Route of Administration 85
Assessment by Molecule Type 87
Drug Profiles 89
pridopidine - Drug Profile 89
dutetrabenazine - Drug Profile 91
Coenzyme Q10 - Drug Profile 92
cysteamine DR - Drug Profile 93
laquinimod sodium - Drug Profile 96
PF-02545920 - Drug Profile 99
OMS-824 - Drug Profile 100
selisistat - Drug Profile 101
PBT-2 - Drug Profile 103
BN-82451 - Drug Profile 105
SOM-3355 - Drug Profile 106
SRX-251 - Drug Profile 107
SRX-246 - Drug Profile 109
NP-03 - Drug Profile 111
PBF-999 - Drug Profile 113
dipraglurant IR - Drug Profile 114
ALN-HTT - Drug Profile 115
olesoxime - Drug Profile 116
AN-726 - Drug Profile 119
CX-929 - Drug Profile 120
VAR-10300 - Drug Profile 121
AMT-090 - Drug Profile 123
noscapine - Drug Profile 124
NsG-33 - Drug Profile 125
Stem Cell Therapy for Neurodegenerative Disorders - Drug Profile 126
PRO-289 - Drug Profile 128
OMS-527 - Drug Profile 129
Small Molecules to Inhibit LSD-1 And MAO-B for Huntington Disease - Drug Profile 131
GM-609 - Drug Profile 132
NSI-566 - Drug Profile 133
NTCELL - Drug Profile 135
INT-41 - Drug Profile 137
OXD-4 - Drug Profile 139
JM-6 - Drug Profile 140
RDC-5 - Drug Profile 141
JRP-655 - Drug Profile 143
JRP-900 - Drug Profile 144
ISIS-HTTRx - Drug Profile 145
ZFP Transcription Factors for Huntington's Disease - Drug Profile 146
XJB-5-131 - Drug Profile 147
VCE-003 - Drug Profile 148
AK-7 - Drug Profile 149
Small Molecule to Inhibit PDE10 for Schizophrenia and Huntington's Disease - Drug Profile 150
Small Molecules to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile 151
OSU-6162 - Drug Profile 153
AZP-2006 - Drug Profile 154
ORY-2001 - Drug Profile 156
Pep42-TAT Peptide - Drug Profile 157
Synthetic Peptide to Inhibit Calmodulin for Huntingtons Disease - Drug Profile 158
OGCx-833 - Drug Profile 159
Peptide to Activate GIPR for CNS, Metabolic Disorders and Trauma - Drug Profile 160
Small Molecule for Huntington Disease - Drug Profile 162
Peptides to Activate GLP-1 Receptor for CNS Disorders and Head Trauma - Drug Profile 163
Stem Cell Therapy for Parkinsons and Huntingtons Diseases - Drug Profile 164
HSB-13 - Drug Profile 165
ENC-1001 - Drug Profile 166
Small Molecule to Inhibit Caspases for Huntington's Disease - Drug Profile 167
Small Molecule to Inhibit Kynurenine 3-Monooxygenase for CNS Disorders - Drug Profile 168
Fisetin - Drug Profile 169
CNB-001 - Drug Profile 170
JM-6 - Drug Profile 172
Small Molecules to Inhibit DREAM Protein for Huntingtons Disease - Drug Profile 173
Rycal - Drug Profile 174
ED-11 - Drug Profile 175
Pluripotent Stem Cell Therapy for Huntington's Disease - Drug Profile 176
Small Molecules to Antagonize NMDA receptor for Huntington's Disease - Drug Profile 177
siRNA for Huntingtons Disease - Drug Profile 178
JR-100 - Drug Profile 179
Small Molecules to Inhibit PDE-10A for Huntingtons Disease - Drug Profile 180
Small Molecules to Inhibit Caspase-6 for Huntingtons Disease - Drug Profile 181
Gene Therapy to Activate CNTF for Huntington's Disease - Drug Profile 182
VCE-0032 - Drug Profile 183
KBND-002 - Drug Profile 184
OXD-5 - Drug Profile 185
Stem Cell Therapy to Inhibit Huntingtin Protein for Huntington's Disease - Drug Profile 186
Stem Cell Therapy to Activate BDNF for Huntington's Disease - Drug Profile 188
NNI-370 - Drug Profile 189
Small Molecules to Inhibit TNFR1 for Immunology, Gastrointestinal, Neurology and Hematological Disorders - Drug Profile 190
Small Molecule for Huntington's Disease - Drug Profile 191
Small Molecule Targeting Protein Kinase For Huntington's Disease - Drug Profile 192
Small Molecules for Huntington's Disease - Drug Profile 193
Small Molecule for Parkinsons Disease and Huntingtons Disease - Drug Profile 194
RNAi Oligonucleotide for Huntingtons Disease - Drug Profile 195
Small Molecules for Huntingtons Disease - Drug Profile 196
Small Molecules to Antagonize NMDA Receptor for Neurodegenerative Disorders - Drug Profile 197
Recombinant Protein for Alzheimer's Disease and Huntington's Disease - Drug Profile 198
Drugs for Huntington Disease - Drug Profile 199
Huntingtin Toxicity Inhibitors - Drug Profile 200
Small Molecule for Huntingtons Disease - Drug Profile 201
Small Molecules for Neurodegenerative Disease - Drug Profile 202
Small Molecules to Inhibit Huntingtin Protein for Huntington's Disease - Drug Profile 203
Small Molecule-1 for Huntington 's Disease - Drug Profile 204
Small Molecule-2 for Huntington 's Disease - Drug Profile 205
Small Molecules for Huntington's Disease - Drug Profile 206
Memantine Nitrone - Drug Profile 207
Synthetic Peptides for Huntington's Disease - Drug Profile 208
Huntington's Disease - Recent Pipeline Updates 210
Huntington's Disease - Dormant Projects 255
Huntington's Disease - Discontinued Products 259
Huntington's Disease - Product Development Milestones 260
Featured News & Press Releases 260
Appendix 269
Methodology 269
Coverage 269
Secondary Research 269
Primary Research 269
Expert Panel Validation 269
Contact Us 270
Disclaimer 270

List of Tables
Number of Products under Development for Huntington's Disease, H2 2014 18
Number of Products under Development for Huntington's Disease - Comparative Analysis, H2 2014 19
Number of Products under Development by Companies, H2 2014 21
Number of Products under Development by Companies, H2 2014 (Contd..1) 22
Number of Products under Development by Companies, H2 2014 (Contd..2) 23
Number of Products under Development by Companies, H2 2014 (Contd..3) 24
Number of Products under Investigation by Universities/Institutes, H2 2014 26
Number of Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 27
Comparative Analysis by Late Stage Development, H2 2014 28
Comparative Analysis by Clinical Stage Development, H2 2014 29
Comparative Analysis by Early Stage Development, H2 2014 30
Products under Development by Companies, H2 2014 31
Products under Development by Companies, H2 2014 (Contd..1) 32
Products under Development by Companies, H2 2014 (Contd..2) 33
Products under Development by Companies, H2 2014 (Contd..3) 34
Products under Investigation by Universities/Institutes, H2 2014 35
Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 36
Huntington's Disease - Pipeline by NsGene A/S, H2 2014 37
Huntington's Disease - Pipeline by Isis Pharmaceuticals, Inc., H2 2014 38
Huntington's Disease - Pipeline by Sangamo BioSciences, Inc., H2 2014 39
Huntington's Disease - Pipeline by Ipsen S.A., H2 2014 40
Huntington's Disease - Pipeline by Pfizer Inc., H2 2014 41
Huntington's Disease - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 42
Huntington's Disease - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2014 43
Huntington's Disease - Pipeline by BrainStorm Cell Therapeutics Inc., H2 2014 44
Huntington's Disease - Pipeline by Addex Therapeutics Ltd, H2 2014 45
Huntington's Disease - Pipeline by Evotec AG, H2 2014 46
Huntington's Disease - Pipeline by Neuralstem, Inc., H2 2014 47
Huntington's Disease - Pipeline by Living Cell Technologies Limited, H2 2014 48
Huntington's Disease - Pipeline by Cortex Pharmaceuticals, Inc., H2 2014 49
Huntington's Disease - Pipeline by Acadia Pharmaceuticals Inc., H2 2014 50
Huntington's Disease - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2014 51
Huntington's Disease - Pipeline by Prana Biotechnology Limited, H2 2014 52
Huntington's Disease - Pipeline by CrystalGenomics, Inc., H2 2014 53
Huntington's Disease - Pipeline by Oryzon Genomics S.A., H2 2014 54
Huntington's Disease - Pipeline by Auspex Pharmaceuticals, Inc., H2 2014 55
Huntington's Disease - Pipeline by reMYND, H2 2014 56
Huntington's Disease - Pipeline by Trophos SA, H2 2014 57
Huntington's Disease - Pipeline by NeuroNascent, Inc., H2 2014 58
Huntington's Disease - Pipeline by Azevan Pharmaceuticals, Inc., H2 2014 59
Huntington's Disease - Pipeline by Siena Biotech S.p.A., H2 2014 60
Huntington's Disease - Pipeline by KineMed, Inc., H2 2014 61
Huntington's Disease - Pipeline by Omeros Corporation, H2 2014 62
Huntington's Disease - Pipeline by Provid Pharmaceuticals, Inc., H2 2014 63
Huntington's Disease - Pipeline by Galenea Corp., H2 2014 64
Huntington's Disease - Pipeline by Genethon, H2 2014 65
Huntington's Disease - Pipeline by Vybion, Inc., H2 2014 66
Huntington's Disease - Pipeline by Treventis Corporation, H2 2014 67
Huntington's Disease - Pipeline by Varinel, Inc., H2 2014 68
Huntington's Disease - Pipeline by Prosensa Therapeutics B.V., H2 2014 69
Huntington's Disease - Pipeline by VivaCell Biotechnology Espana S.L., H2 2014 70
Huntington's Disease - Pipeline by Medesis Pharma S.A., H2 2014 71
Huntington's Disease - Pipeline by Genervon Biopharmaceuticals, LLC, H2 2014 72
Huntington's Disease - Pipeline by BioCrea GmbH, H2 2014 73
Huntington's Disease - Pipeline by Zenobia Therapeutics, Inc., H2 2014 74
Huntington's Disease - Pipeline by AlzProtect SAS, H2 2014 75
Huntington's Disease - Pipeline by SOM Biotech SL, H2 2014 76
Huntington's Disease - Pipeline by Valens Therapeutics, Inc., H2 2014 77
Huntington's Disease - Pipeline by EncephRx, Inc., H2 2014 78
Huntington's Disease - Pipeline by Chronos Therapeutics Limited, H2 2014 79
Huntington's Disease - Pipeline by UniQure NV, H2 2014 80
Huntington's Disease - Pipeline by Angita B.V., H2 2014 81
Huntington's Disease - Pipeline by Saniona AB, H2 2014 82
Assessment by Monotherapy Products, H2 2014 83
Number of Products by Stage and Target, H2 2014 86
Number of Products by Stage and Mechanism of Action, H2 2014 90
Number of Products by Stage and Route of Administration, H2 2014 93
Number of Products by Stage and Molecule Type, H2 2014 95
Huntington's Disease Therapeutics - Recent Pipeline Updates, H2 2014 217
Huntington's Disease - Dormant Projects, H2 2014 262
Huntington's Disease - Dormant Projects (Contd..1), H2 2014 263
Huntington's Disease - Dormant Projects (Contd..2), H2 2014 264
Huntington's Disease - Dormant Projects (Contd..3), H2 2014 265
Huntington's Disease - Discontinued Products, H2 2014 266